Benign, persistent, and invasive: mechanistic and translational approaches to middle-ear cholesteatoma

Abstract

Acquired middle-ear cholesteatoma is a histologically benign keratinizing squamous epithelial lesion that paradoxically exhibits locally destructive, recurrent, and invasive behavior, often resulting in ossicular erosion, hearing loss, labyrinthine fistula, and, rarely, intracranial complications. Surgical excision remains the primary management strategy; however, recurrence is common due to persistent microenvironmental drivers. Recent mechanistic studies-including single-cell transcriptomics, spatial proteomics, and epigenetic profiling-reveal a multifactorial pathogenesis orchestrated by chronic inflammation, proteolytic extracellular-matrix remodeling, osteoclast activation via RANKL and activin A, epithelial plasticity with partial epithelial-to-mesenchymal transition (EMT), and a dysbiotic, biofilm-forming microbiome. Emerging evidence further implicates oxidative stress, RNA and epigenetic modifications, miRNA dysregulation, and immune cell infiltration as central modulators of lesion chronicity and bone resorption. Collectively, these processes establish a self-sustaining pro-osteolytic microenvironment that drives bone erosion and postoperative recurrence. Cholesteatoma recapitulates several features of malignant lesions-hyperproliferation, local invasion, and stromal/immune cell recruitment-yet remains fundamentally benign, lacking metastatic potential and genomic instability. Its aggression is ecological rather than genetic, highlighting the potential for microenvironment-directed, precision-based strategies. Adjunctive approaches may include local delivery of modulatory agents, targeted interference with inflammatory, proteolytic, osteoclastogenic, and microbial axes, and biomarker-guided patient stratification. Preclinical and early-phase experimental studies assessing target engagement, radiologic stabilization, and molecular surrogates of efficacy could inform safer, mechanism-driven interventions that complement surgery, reduce recurrence, and preserve hearing. Integrating molecular pathobiology with clinical strategy positions cholesteatoma as a model for benign yet locally aggressive, microenvironment-driven disease, providing a roadmap for translational therapies with direct relevance to surgical practice.

Keywords

cholesteatoma / middle ear / recurrence / oxidative stress / inflammation / bone erosion / epigenetics / microbiome

References

[1] Kennedy KL, Singh AK. Middle Ear Cholesteatoma. Treasure Island (FL): StatPearls Publishing; 2025.

[2] Delsmann MM, Bonik P, Ocokoljic A, Häussler SM, Püschel K, Praetorius M, et al. Cholesteatoma Severely Impacts the Integrity and Bone Material Quality of the Incus. Calcif Tissue Int. 2023; 113: 609-17.

[3] Massoud S, Farhat R, Abd Elhadi U, Awawde R, Merchavy S, Safia A. Incidence Rate and Determinants of Recurrent Cholesteatoma Following Surgical Management: A Systematic Review, Subgroup, and Meta-Regression Analysis. Biomedicines. 2025; 13: 2506.

[4] Rosito LS, Netto LF, Teixeira AR, da Costa SS. Classification of Cholesteatoma According to Growth Patterns. JAMA Otolaryngol Head Neck Surg. 2016; 142: 168-72.

[5] Aquino JE, Cruz Filho NA, de Aquino JN. Epidemiology of middle ear and mastoid cholesteatomas: study of 1146 cases. Braz J Otorhinolaryngol. 2011; 77: 341-7.

[6] Xing B, Dang Y, Xi K. Cholesteatoma: An Updated Review of Molecular Pathogenesis and Potential Therapeutic Directions. Curr Med Chem. 2025.

[7] Suchozebrska-Jesionek D, Szymański M, Kurzepa J, Gołabek W, Stryjecka-Zimmer M. Gelatinolytic activity of matrix metalloproteinases 2 and 9 in middle ear cholesteatoma. J Otolaryngol Head Neck Surg. 2008; 37: 628-32.

[8] Zamfir-Chiru-Anton A, Manda D, Gheorghe DC. Emerging Paradigms in Cholesteatoma: From a Traditional Approach to Personalized Therapy. Int J Mol Sci. 2025; 26: 9545.

[9] Fallon K, Chi D, Remenschneider A. Management of Cholesteatoma: Surgical Options for Disease Limited to Middle Ear/Mastoid. Otolaryngol Clin North Am. 2025; 58: 75-87.

[10] Schürmann M, Oppel F, Shao S, Volland-Thurn V, Kaltschmidt C, Kaltschmidt B, et al. Chronic inflammation of middle ear cholesteatoma promotes its recurrence via a paracrine mechanism. Cell Commun Signal. 2021; 19: 25.

[11] Shimizu K, Kikuta J, Ohta Y, Uchida Y, Miyamoto Y, Morimoto A, et al. Single-cell transcriptomics of human cholesteatoma identifies an activin A-producing osteoclastogenic fibroblast subset inducing bone destruction. Nat Commun. 2023; 14: 4417.

[12] Hamed MA, Nakata S, Sayed RH, Ueda H, Badawy BS, Nishimura Y, et al. Pathogenesis and Bone Resorption in Acquired Cholesteatoma: Current Knowledge and Future Prospectives. Clin Exp Otorhinolaryngol. 2016; 9: 298-308.

[13] Dambergs K, Sumeraga G, Pilmane M. Morphopathogenesis of Adult Acquired Cholesteatoma. Medicina (Kaunas). 2023; 59: 306.

[14] Lei Y, An J, Ren Q, Wang M, Gao M. Expression of MMP-14 and its role in bone destruction in middle ear cholesteatoma: A prospective observational study. Medicine (Baltimore). 2023; 102: e35538.

[15] Jeong JH, Park CW, Tae K, Lee SH, Shin DH, Kim KR, et al. Expression of RANKL and OPG in middle ear cholesteatoma tissue. Laryngoscope. 2006; 116: 1180-4.

[16] Zeng L, Xie L, Hu J, He C, Liu A, Lu X, et al. Osteopontin-driven partial epithelial-mesenchymal transition governs the development of middle ear cholesteatoma. Cell Cycle. 2024; 23: 537-54.

[17] Jesic S, Jotic A, Tomanovic N, Zivkovic M. Expression of toll-like receptors 2, 4 and nuclear factor kappa B in mucosal lesions of human otitis: pattern and relationship in a clinical immunohistochemical study. Ann Otol Rhinol Laryngol. 2014; 123: 434-41.

[18] Frank DN, Magno JPM, Velasco KJS, Bootpetch TC, Salud JED, David KJV, et al. Microbiota Associated With Cholesteatoma Tissue in Chronic Suppurative Otitis Media. Front Cell Infect Microbiol. 2022; 12: 746428.

[19] Schürmann M, Greiner JFW, Volland-Thurn V, Oppel F, Kaltschmidt C, Sudhoff H, et al. Stem Cell-Induced Inflammation in Cholesteatoma is Inhibited by the TLR4 Antagonist LPS-RS. Cells. 2020; 9: 199.

[20] Meng L, Liu S, Luo J, Tu Y, Li T, Li P, et al. Oxidative stress and reactive oxygen species in otorhinolaryngological diseases: insights from pathophysiology to targeted antioxidant therapies. Redox Rep. 2025; 30: 2458942.

[21] Yamamoto-Fukuda T, Akiyama N, Kojima H. Super-enhancer Acquisition Drives FOXC2 Expression in Middle Ear Cholesteatoma. J Assoc Res Otolaryngol. 2021; 22: 405-24.

[22] Xie S, Jin L, He J, Fu J, Yin T, Ren J, et al. Analysis of mRNA m⁶A modification and mRNA expression profiles in middle ear cholesteatoma. Front Genet. 2023; 14: 1188048.

[23] Dżaman K, Czerwaty K, Reichert TE, Szczepański MJ, Ludwig N. Expression and Regulatory Mechanisms of MicroRNA in Cholesteatoma: A Systematic Review. Int J Mol Sci. 2023; 24: 12277.

[24] Xie M, Tang Q, Wang S, Huang X, Wu Z, Han Z, et al. Identification of miRNA expression profile in middle ear cholesteatoma using small RNA-sequencing. BMC Med Genomics. 2024; 17: 162.

[25] Gong N, Zhu W, Xu R, Teng Z, Deng C, Zhou H, et al. Keratinocytes-derived exosomal miRNA regulates osteoclast differentiation in middle ear cholesteatoma. Biochem Biophys Res Commun. 2020; 525: 341-7.

[26] Bassiouni M, Arens P, Zabaneh SI, Olze H, Horst D, Roßner F. The Relationship between the M1/M2 Macrophage Polarization and the Degree of Ossicular Erosion in Human Acquired Cholesteatoma: An Immunohistochemical Study. J Clin Med. 2022; 11: 4826.

[27] Özdemir Ç, Kuzu S, Şenol Y, Yiğit T, Güldün E, Bucak A, et al. A role for mast cell-mediated antibodies in the formation of cholesteatoma and cholesteatoma-induced bone erosion. Diagnostics (Basel). 2023; 13: 455.

[28] Satoh C, Yoshiura K, Mishima H, Yoshida H, Takahashi H, Kumai Y. Proto-oncogene mutations in middle ear cholesteatoma contribute to its pathogenesis. BMC Med Genomics. 2023; 16: 288.

[29] Castle JT. Cholesteatoma Pearls: Practical Points and Update. Head Neck Pathol. 2018; 12: 419-29.

[30] Kashfi Sadabad R, Xia A, Benkafadar N, Faniku C, Preciado D, Yang S, et al. Topical Delivery of Elastic Liposomal Vesicles for Treatment of Middle and Inner Ear Diseases. ACS Appl Bio Mater. 2022; 5: 4849-59.

[31] Delaney DS, Liew LJ, Lye J, Atlas MD, Wong EYM. Overcoming barriers: a review on innovations in drug delivery to the middle and inner ear. Front Pharmacol. 2023; 14: 1207141.

[32] Raynov AM, Choung YH, Park HY, Choi SJ, Park K. Establishment and characterization of an in vitro model for cholesteatoma. Clin Exp Otorhinolaryngol. 2008; 1: 86-91.

[33] Laeeq S, Faust R. Modeling the cholesteatoma microenvironment: coculture of HaCaT keratinocytes with WS1 fibroblasts induces MMP-2 activation, invasive phenotype, and proteolysis of the extracellular matrix. Laryngoscope. 2007; 117: 313-8.

[34] Yamamoto-Fukuda T, Takahashi H, Koji T. Animal models of middle ear cholesteatoma. J Biomed Biotechnol. 2011; 2011: 394241.

[35] Takahashi H, Funabiki K, Hasebe S, Fukuda-Yamamoto T, Kaieda S, Iwanaga T, et al. Clinical efficacy of 5-fluorouracil (5-FU) topical cream for treatment of cholesteatoma. Auris Nasus Larynx. 2005; 32: 353-7.